Lakefront Biotherapeutics (LKFT) Other Non-Current Liabilities (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Other Non-Current Liabilities data on file, last reported at $16.1 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $16.1 million, down 43.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.1 million (down 43.33% YoY), and the FY2025 annual result was $14.7 million, down 59.41% from the prior year.
• Other Non-Current Liabilities climbed to $16.1 million in Q1 2026 per LKFT's latest filing, from $14.7 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $46.6 million in Q1 2024 and troughed at $10.7 million in Q1 2022.
• A 5-year average of $27.3 million and a median of $28.3 million in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Other Non-Current Liabilities surged 172.59% in 2022, then tumbled 59.41% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $22.2 million in 2022, then jumped by 52.67% to $34.0 million in 2023, then advanced by 6.4% to $36.1 million in 2024, then plunged by 59.41% to $14.7 million in 2025, then climbed by 10.03% to $16.1 million in 2026.
• Business Quant data shows LKFT's Other Non-Current Liabilities at $16.1 million in Q1 2026, $14.7 million in Q4 2025, and $28.3 million in Q3 2025.